| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kathleen S Lynch, Michael J Rya. Understanding the Role of Incentive Salience in Sexual Decision-Making. Integrative and comparative biology. vol 60. issue 3. 2021-06-17. PMID:32483613. |
this review includes studies of dopamine agonist or antagonist administration in females during mate choice or partner preference tests, measures of neural activity in dopaminergic neural circuits during mate choice or partner preference tests, and social regulation of dopamine in females when entering reproductive contexts and/or exposure to mate signals. |
2021-06-17 |
2023-08-13 |
Not clear |
| M E Chávez-Pichardo, D Y Reyes-Bravo, M S Mendoza-Trejo, A G Marín-López, M Giordano, N Hernández-Chan, K Domínguez-Marchan, L C Ortega-Rosales, V M Rodrígue. Brain alterations in GABA, glutamate and glutamine markers after chronic atrazine exposure in the male albino rat. Archives of toxicology. vol 94. issue 9. 2021-06-16. PMID:32561961. |
studies in rodents have shown that chronic atr exposure is associated with alterations in the nigrostriatal dopaminergic pathway such as hyperactivity, decreased striatal dopamine levels, and diminished numbers of tyrosine hydroxylase positive cells in substantia nigra pars compacta. |
2021-06-16 |
2023-08-13 |
rat |
| Victoria Sofie Witzig, Daniel Komnig, Björn H Falkenburge. Changes in Striatal Medium Spiny Neuron Morphology Resulting from Dopamine Depletion Are Reversible. Cells. vol 9. issue 11. 2021-06-16. PMID:33182316. |
in order to define the potential benefits and limitations of dopamine substitution, we tested in a mouse model whether dendritic pruning and spine loss can be reversible when dopaminergic axon terminals regenerate. |
2021-06-16 |
2023-08-13 |
mouse |
| Yun Tang, Xiao-Ke Yang, Xin-Wei Zhang, Wen-Tao Wu, Fu-Li Zhang, Hong Jiang, Yan-Ling Liu, Christian Amatore, Wei-Hua Huan. Harpagide, a natural product, promotes synaptic vesicle release as measured by nanoelectrode amperometry. Chemical science. vol 11. issue 3. 2021-06-15. PMID:34123052. |
parkinson's disease (pd) is a neurodegenerative disorder characterized by progressive loss of dopaminergic (daergic) neurons and low level of dopamine (da) in the midbrain. |
2021-06-15 |
2023-08-13 |
Not clear |
| J A Cota-Coronado, S Sandoval-Ávila, Y P Gaytan-Dávila, N F Diaz, B Vega-Ruiz, E Padilla-Camberos, N E Díaz-Martíne. New transgenic models of Parkinson's disease using genome editing technology. Neurologia (Barcelona, Spain). vol 35. issue 7. 2021-06-14. PMID:29196142. |
it is characterised by selective loss of dopaminergic neurons in the substantia nigra pars compacta, which results in dopamine depletion, leading to a number of motor and non-motor symptoms. |
2021-06-14 |
2023-08-13 |
Not clear |
| Mohammad Shimia, Arad Iranmehr, Amir Valizadeh, Farhad Mirzaei, Mohamad Namvar, Ebrahim Rafiei, Ahsan Rahimi, Aida Khadivi, Kamkar Aeinfa. A placebo-controlled randomized clinical trial of amantadine hydrochloride for evaluating the functional improvement of patients following severe acute traumatic brain injury. Journal of neurosurgical sciences. 2021-06-11. PMID:34114429. |
considering the known derangements in the dopaminergic neurotransmitter systems following traumatic brain injury (tbi), dopamine agonists are used as a pharmacologic option. |
2021-06-11 |
2023-08-13 |
Not clear |
| Jonathan R Isaacson, Salima Brillman, Nisha Chhabria, Stuart H Isaacso. Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson's Disease. Journal of Parkinson's disease. vol 11. issue 2. 2021-06-10. PMID:33554925. |
the diagnosis of parkinson's disease (pd) is primarily clinical, but in cases of diagnostic uncertainty, evaluation of nigrostriatal dopaminergic degeneration (nsdd) by imaging of the dopamine transporter using datscan with single-photon emission computed tomography (spect) brain imaging may be helpful. |
2021-06-10 |
2023-08-13 |
Not clear |
| Marte I Flydal, Trond-André Kråkenes, Mary Dayne S Tai, Maria P A Tran, Knut Teigen, Aurora Martine. Levalbuterol lowers the feedback inhibition by dopamine and delays misfolding and aggregation in tyrosine hydroxylase. Biochimie. vol 183. 2021-06-09. PMID:33309753. |
th - and subsequently dopamine - is also reduced in parkinson's disease (pd) due to the selective death of dopaminergic neurons. |
2021-06-09 |
2023-08-13 |
human |
| Javier García-Pardo, Fernando Novio, Fabiana Nador, Ivana Cavaliere, Salvio Suárez-García, Silvia Lope-Piedrafita, Ana Paula Candiota, Jordi Romero-Gimenez, Beatriz Rodríguez-Galván, Jordi Bové, Miquel Vila, Julia Lorenzo, Daniel Ruiz-Molin. Bioinspired Theranostic Coordination Polymer Nanoparticles for Intranasal Dopamine Replacement in Parkinson's Disease. ACS nano. vol 15. issue 5. 2021-06-09. PMID:33885286. |
dopamine (da) is one of the main neurotransmitters found in the central nervous system and has a vital role in the function of dopaminergic (dargic) neurons. |
2021-06-09 |
2023-08-13 |
Not clear |
| Chen-Meng Qiao, Meng-Fei Sun, Xue-Bing Jia, Yang Li, Bo-Ping Zhang, Li-Ping Zhao, Yun Shi, Zhi-Lan Zhou, Ying-Li Zhu, Chun Cui, Yan-Qin She. Sodium Butyrate Exacerbates Parkinson's Disease by Aggravating Neuroinflammation and Colonic Inflammation in MPTP-Induced Mice Model. Neurochemical research. vol 45. issue 9. 2021-06-08. PMID:32556930. |
interestingly, nab significantly aggravated mptp-induced motor dysfunction (p < 0.01), decreased dopamine (p < 0.05) and 5-ht (p < 0.05) levels, exacerbated declines of dopaminergic neurons (34%, p < 0.05) and downregulated expression of tyrosine hydroxylase (th, 47%, p < 0.05), potentiated glia-mediated neuroinflammation by increasing the number of microglia (17%, p < 0.05) and activating astrocytes (28%, p < 0.01). |
2021-06-08 |
2023-08-13 |
mouse |
| Siqi Luo, Libo Du, Yan Cu. Potential Therapeutic Applications and Developments of Exosomes in Parkinson's Disease. Molecular pharmaceutics. vol 17. issue 5. 2021-06-07. PMID:32227966. |
current treatments alleviate the symptoms through the administration of drugs, including dopamine precursors, dopamine metabolism inhibitors, and activated dopamine agonists, but they cannot prevent the ongoing dopaminergic damage. |
2021-06-07 |
2023-08-13 |
Not clear |
| Lorena Jiménez-Sánchez, Javier Blesa, Natalia L Del Rey, Mariana H G Monje, José A Obeso, Carmen Cavad. Serotonergic innervation of the striatum in a nonhuman primate model of Parkinson's disease. Neuropharmacology. vol 170. 2021-06-03. PMID:31589886. |
parkinson's disease (pd) is characterized by dopaminergic neurodegeneration in the substantia nigra and dopamine depletion in the striatum. |
2021-06-03 |
2023-08-13 |
monkey |
| Lorena Oliveira de Matos, Ana Luiza de Araujo Lima Reis, Lorena Terene Lopes Guerra, Leonardo de Oliveira Guarnieri, Muiara Aparecida Moraes, Laila Blanc Arabe, Renan Pedra de Souza, Grace Schenatto Pereira, Bruno Rezende Souz. Early postnatal l-Dopa treatment causes behavioral alterations in female vs. male young adult Swiss mice. Neuropharmacology. vol 170. 2021-06-03. PMID:32325324. |
knockout mice for dopamine transporters (dat) as well as site-specific knockout mice lacking dopaminergic d2 autoreceptors in dopaminergic neurons (da-d2rko) display behavioral alterations such as hyperlocomotion and abnormal prepulse inhibition. |
2021-06-03 |
2023-08-13 |
mouse |
| Della Grace Thomas Parambi, Uzma Saleem, Muhammad Ajmal Shah, Fareeha Anwar, Bashir Ahmad, Amna Manzar, Aqsa Itzaz, Seetha Harilal, Md Sahab Uddin, Hoon Kim, Bijo Mathe. Exploring the Therapeutic Potentials of Highly Selective Oxygenated Chalcone Based MAO-B Inhibitors in a Haloperidol-Induced Murine Model of Parkinson's Disease. Neurochemical research. vol 45. issue 11. 2021-06-02. PMID:32939670. |
parkinson's disease (pd) is a neurodegenerative disorder of dopaminergic, noradrenergic, and serotonergic systems, in which dopamine, noradrenaline, and serotonin levels are depleted and lead to the development of motor and non-motor symptoms such as tremor, bradykinesia, weight changes, fatigue, depression, and visual hallucinations. |
2021-06-02 |
2023-08-13 |
Not clear |
| Liesbeth Reneman, Marieke van der Pluijm, Anouk Schrantee, Elsmarieke van de Giesse. Imaging of the dopamine system with focus on pharmacological MRI and neuromelanin imaging. European journal of radiology. vol 140. 2021-06-02. PMID:34004428. |
neuromelanin is located in the cell bodies of dopaminergic neurons of the nigrostriatal pathway and can be used as a proxy measure for long term dopamine function or degeneration of dopaminergic neurons. |
2021-06-02 |
2023-08-13 |
Not clear |
| Pia M Vidal, Rodrigo Pachec. Targeting the Dopaminergic System in Autoimmunity. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 15. issue 1. 2021-05-27. PMID:30661214. |
thus, impaired dopaminergic signalling through different dopamine receptors may result in altered behaviour of immunity, contributing to the development and progression of autoimmune pathologies. |
2021-05-27 |
2023-08-13 |
Not clear |
| Mikhail Melnikov, Vladimir Rogovskii, Alexey Boykо, Mikhail Pashenko. Dopaminergic Therapeutics in Multiple Sclerosis: Focus on Th17-Cell Functions. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 15. issue 1. 2021-05-27. PMID:31011885. |
recent studies have shown that dopamine can enhance or inhibit the functions of innate and adaptive immune system, depending on the activation of different dopaminergic receptors, and can therefore influence the course of experimental autoimmune encephalomyelitis (eae) and ms. |
2021-05-27 |
2023-08-13 |
Not clear |
| Silvia Capellin. Dopaminergic Agents in Rheumatoid Arthritis. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 15. issue 1. 2021-05-27. PMID:31016462. |
while more research is necessary to accurately determine the effect of dopamine in ra, these results are encouraging and support a possible use of dopaminergic drugs for the treatment of arthritis in the future. |
2021-05-27 |
2023-08-13 |
Not clear |
| S M Matt, P J Gaskil. Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 15. issue 1. 2021-05-27. PMID:31077015. |
many immune cells express dopamine receptors and other dopamine related proteins, enabling them to actively respond to dopamine and suggesting that dopaminergic immunoregulation is an important part of proper immune function. |
2021-05-27 |
2023-08-13 |
human |
| Firoz Anwar, Salma Naqvi, Fahad A Al-Abbasi, Nauroz Neelofar, Vikas Kumar, Ankit Sahoo, Mohammad Amjad Kama. Targeting COVID-19 in Parkinson's Patients: Drugs Repurposed. Current medicinal chemistry. vol 28. issue 12. 2021-05-27. PMID:32881656. |
alteration in dopaminergic neurons and deficiency of dopamine in pd patients are the most common symptoms affecting 1% population above the age of 60 years. |
2021-05-27 |
2023-08-13 |
Not clear |